Sanctuary Advisors LLC Invests $649,000 in Royalty Pharma plc (NASDAQ:RPRX)

Sanctuary Advisors LLC purchased a new stake in shares of Royalty Pharma plc (NASDAQ:RPRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 23,178 shares of the biopharmaceutical company’s stock, valued at approximately $649,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Inspire Investing LLC increased its position in shares of Royalty Pharma by 175.1% in the first quarter. Inspire Investing LLC now owns 43,524 shares of the biopharmaceutical company’s stock valued at $1,322,000 after acquiring an additional 27,701 shares during the period. New Century Financial Group LLC purchased a new stake in Royalty Pharma in the 1st quarter worth approximately $1,091,000. Swedbank AB grew its position in shares of Royalty Pharma by 30.6% in the 2nd quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company’s stock worth $285,151,000 after buying an additional 2,533,570 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in shares of Royalty Pharma by 5.2% during the first quarter. Canada Pension Plan Investment Board now owns 923,639 shares of the biopharmaceutical company’s stock valued at $28,051,000 after buying an additional 45,839 shares during the period. Finally, Tidal Investments LLC raised its holdings in shares of Royalty Pharma by 28.2% during the first quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company’s stock valued at $2,740,000 after acquiring an additional 19,834 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on RPRX shares. The Goldman Sachs Group lifted their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Morgan Stanley boosted their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. Finally, StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Royalty Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Royalty Pharma Price Performance

Shares of RPRX opened at $27.87 on Tuesday. Royalty Pharma plc has a fifty-two week low of $25.20 and a fifty-two week high of $31.66. The firm’s 50-day simple moving average is $27.87 and its two-hundred day simple moving average is $27.71. The stock has a market cap of $16.54 billion, a PE ratio of 24.66, a price-to-earnings-growth ratio of 4.05 and a beta of 0.46. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. During the same quarter in the prior year, the business posted $0.85 EPS. Analysts anticipate that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 3.01%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s dividend payout ratio is presently 74.34%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.